** Drugmaker BioCryst Pharmaceuticals' BCRX.O shares fall 11% to $8.20
** Co posts Q4 net loss of 13 cents per share, compared with analysts' estimates of a loss of 6 cents per share, according to data compiled by LSEG
** Separately in a filing, co discloses it received a notice from India's Annora Pharma in January regarding Annora's submission of an application to the FDA seeking approval to manufacture, use or sell a generic version of BCRX's Orladeyo before the expiration of patents
** The letter alleges that the patents, which expire in 2039, are invalid
** Orladeyo is used to prevent attacks of hereditary angioedema, a rare genetic disorder that causes severe swelling in the body
** BCRX intends to vigorously defend its intellectual property rights protecting Orladeyo, it said
** Co posts Q4 revenue of $131.5 million on strong sales for Orladeyo, compared with analysts' estimates of $130.2 million
** Expects 2025 total revenue between $560 million and $575 million vs analysts' estimates $545 million
** BCRX rose 63% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。